AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11509476 — intervention group
Group type: COMPARATOR
Intervention: Salt-resistant group (baseline)
Number of subjects: 158
Study 11509476 — intervention group
Group type: COMPARATOR
Intervention: Chronic salt-sensitive group (baseline)
Number of subjects: 158
Study 11509476 — intervention group
Group type: COMPARATOR
Intervention: Chronic salt-resistant group (baseline)
Number of subjects: 158
Study 9240990 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 364
Study 9240990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 8237822 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillator (ICD) therapy
Number of subjects: 400
Study 8237822 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 400
Study 3443058 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain felodipine tablets, 10mg bid for 10 days
Number of subjects: 2
Study 3443058 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release felodipine, 20mg once every morning
Number of subjects: 2
Study 3443058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 29802967 — intervention group
Group type: EXPERIMENTAL
Intervention: Manhood 2.0 program
Number of subjects: 866
Study 29802967 — intervention group
Group type: COMPARATOR
Intervention: Job readiness training program
Number of subjects: 866
Study 27923862 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing-informed strategy during group orientations
Number of subjects: 90
Study 24955731 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA diet supplementation (1.14 g per day for eight weeks)
Number of subjects: 15
Study 24955731 — intervention group
Group type: EXPERIMENTAL
Intervention: Training season and acute exercise
Number of subjects: 15
Study 24955731 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) group
Number of subjects: 15
Study 22249017 — intervention group
Group type: EXPERIMENTAL
Intervention: Dix-Hallpike manoeuvre performed in the morning and afternoon sequence.
Number of subjects: 50
Study 20849609 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women (BMI 30-34.9 kg/m2)
Number of subjects: 1661
Study 20849609 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight women (BMI 25-29.9 kg/m2)
Number of subjects: 1661
Study 20849609 — intervention group
Group type: EXPERIMENTAL
Intervention: Babies of obese women (BMI 30-34.9 kg/m2)
Number of subjects: 1661
Study 18201893 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (15 ml bolus, 10 ml every 6h)
Number of subjects: 70
Study 18201893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (20 ml bolus, 15 ml every 6h)
Number of subjects: 70
Study 18201893 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Thoracotomy with Bupivacaine
Number of subjects: 70
Study 18201893 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Thoracotomy with Ropivacaine
Number of subjects: 70
Study 18201893 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral Thoracotomy with Bupivacaine
Number of subjects: 70
Study 18201893 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral Thoracotomy with Ropivacaine
Number of subjects: 70
Study 18201893 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 70
Study 18201893 — intervention group
Group type: COMPARATOR
Intervention: Anterior Thoracotomy vs Posterolateral Thoracotomy
Number of subjects: 70
Study 18201893 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine vs Ropivacaine
Number of subjects: 70
Study 16355302 — intervention group
Group type: COMPARATOR
Intervention: Transcranial and paravertebral magnetic stimulation
Number of subjects: 68
Study 16355302 — intervention group
Group type: COMPARATOR
Intervention: Transcranial stimulation
Number of subjects: 68
Study 12570114 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol
Number of subjects: 20
Study 12570114 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol
Number of subjects: 20
Study 12570114 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol
Number of subjects: 20
Study 12570114 — intervention group
Group type: EXPERIMENTAL
Intervention: oxitropium
Number of subjects: 20
Study 12570114 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 10349064 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1094
Study 7852252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day
Number of subjects: 18
Study 7852252 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 18
Study 1902159 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nitroglycerin patches (mean necessary effective patch dose: 125 sq cm, range 60 to 220 sq cm)
Number of subjects: 8
Study 1902159 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 8
Study 7120957 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-sec interval between responses
Number of subjects: 31
Study 7120957 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-sec interval between responses
Number of subjects: 31
Study 7120957 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence completion and picture naming tasks
Number of subjects: 31
Study 7120957 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased semantic difficulty
Number of subjects: 31
Study 31277151 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand Up and Move More intervention (n=40)
Number of subjects: 80
Study 31277151 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (n=40)
Number of subjects: 80
Study 27753201 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/d) for 12 weeks
Number of subjects: 32
Study 27753201 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 32
Study 27178766 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Number of subjects: 100
Study 27178766 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home rehabilitation plus placebo supplementation
Number of subjects: 100
Study 27178766 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home rehabilitation plus protein supplementation
Number of subjects: 100
Study 27178766 — intervention group
Group type: EXPERIMENTAL
Intervention: Single testosterone injection
Number of subjects: 100
Study 27178766 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo supplementation
Number of subjects: 100
Study 24379118 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular running monocryl suture sealed with 2-octyl cyanoacrylate (OCA)
Number of subjects: 103
Study 24379118 — intervention group
Group type: COMPARATOR
Intervention: Metallic staples
Number of subjects: 103
Study 24379118 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular running monocryl suture sealed with OCA
Number of subjects: 103
Study 22147468 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculated silage (IN) with mixed bacterial culture (1.0 × 10(11) cfu/g Lactobacillus buchneri LN4017, 2.0 × 10(10) cfu/g Lactobacillus plantarum LP7109, 1.0 × 10(10) cfu/g Lactobacillus casei LC3200)
Number of subjects: 0
Study 22147468 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculated silage (IN)
Number of subjects: 0
Study 22147468 — intervention group
Group type: COMPARATOR
Intervention: Control silage (UN)
Number of subjects: 0
Study 19682374 — intervention group
Group type: EXPERIMENTAL
Intervention: clinic + outreach
Number of subjects: 16
Study 19682374 — intervention group
Group type: COMPARATOR
Intervention: clinic only
Number of subjects: 16
Study 17292954 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (2 g or 1 g for 11 patients)
Number of subjects: 70
Study 17292954 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg)
Number of subjects: 70
Study 14749635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg)
Number of subjects: 74
Study 14749635 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 74
Study 9621139 — intervention group
Group type: EXPERIMENTAL
Intervention: pH5 Eucerin aftersun lotion with 10% hamamelis distillate
Number of subjects: 30
Study 9621139 — intervention group
Group type: COMPARATOR
Intervention: Other lotions (vehicle and prior aftersun formulation)
Number of subjects: 30
Study 7939074 — intervention group
Group type: EXPERIMENTAL
Intervention: QD regimen (amlodipine)
Number of subjects: 113
Study 7939074 — intervention group
Group type: COMPARATOR
Intervention: BID regimen (nifedipine SR)
Number of subjects: 113
Study 7939074 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 113
Study 3280325 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 139
Study 3280325 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxazole plus trimethoprim (SXT)
Number of subjects: 139
Study 3280325 — intervention group
Group type: COMPARATOR
Intervention: Oral vancomycin plus colistin (V/C)
Number of subjects: 139
Study 3280325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 3280325 — intervention group
Group type: COMPARATOR
Intervention: V/C
Number of subjects: 139
Study 31845383 — intervention group
Group type: EXPERIMENTAL
Intervention: SPOT-Fold method
Number of subjects: 301
Study 31965768 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (bicycling on lower limb ergometer 4 days/week for 8 weeks)
Number of subjects: 60
Study 31965768 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 60
Study 31965768 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 60
Study 31965768 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 29143667 — intervention group
Group type: EXPERIMENTAL
Intervention: microdose rHuEpo
Number of subjects: 39
Study 29143667 — intervention group
Group type: EXPERIMENTAL
Intervention: adaptive model
Number of subjects: 39
Study 25826606 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy appeal antismoking messages
Number of subjects: 189
Study 25826606 — intervention group
Group type: COMPARATOR
Intervention: Fear appeal messages
Number of subjects: 189
Study 23336474 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted case-finding approach
Number of subjects: 1634
Study 23336474 — intervention group
Group type: COMPARATOR
Intervention: Opportunistic case-finding approach
Number of subjects: 1634
Study 21228725 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant load exercise (60% peak oxygen uptake)
Number of subjects: 23
Study 21228725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise (80% and 40% peak oxygen uptake)
Number of subjects: 23
Study 21228725 — intervention group
Group type: COMPARATOR
Intervention: Both exercise sessions (constant load and intermittent)
Number of subjects: 23
Study 19624590 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH during cardiopulmonary bypass
Number of subjects: 40
Study 19624590 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass
Number of subjects: 40
Study 17164830 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley-containing meals
Number of subjects: 14
Study 17164830 — intervention group
Group type: COMPARATOR
Intervention: Wheat-containing meals
Number of subjects: 14
Study 15281530 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) infusion (4 U/h)
Number of subjects: 42
Study 15281530 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE) infusion alone
Number of subjects: 42
Study 11951146 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta(9)-THC (5.0, 7.5 or 10.0 mg)
Number of subjects: 12
Study 11951146 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta(9)-THC
Number of subjects: 12
Study 11951146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9526750 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation governed by Functional Independence Measure (FIM)
Number of subjects: 34
Study 9526750 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods of rehabilitation
Number of subjects: 34
Study 7925223 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (E)
Number of subjects: 10
Study 7925223 — intervention group
Group type: COMPARATOR
Intervention: Endurance exercise with energy restriction (D+E)
Number of subjects: 10
Study 2477096 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% NaCl/Dextran 70 solution
Number of subjects: 60
Study 2477096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 787449 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 80
Study 787449 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 80
Study 30617461 — intervention group
Group type: EXPERIMENTAL
Intervention: l-bupivacaine (12.5 mg h−1) continuous wound infusion for 48 hours via a pre-sternal multiperforated catheter
Number of subjects: 1493
Study 30617461 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 1493
Study 30617461 — intervention group
Group type: EXPERIMENTAL
Intervention: l-bupivacaine (12.5 mg h−1) continuous wound infusion for 48 hours
Number of subjects: 1493
Study 27832977 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARM score
Number of subjects: 7011
Study 26003664 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression self-care toolkit with lay telephone coaching
Number of subjects: 223
Study 26003664 — intervention group
Group type: COMPARATOR
Intervention: Depression self-care toolkit without lay telephone coaching (control)
Number of subjects: 223
Study 23433430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy snacks
Number of subjects: 40
Study 23433430 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 40
Study 21250913 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPOα therapy (300 IU/kg/dose, 3 times/week, subcutaneously)
Number of subjects: 30
Study 21250913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rHuEPOα therapy)
Number of subjects: 30
Study 19318900 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare Coordinated Care Demonstration intervention
Number of subjects: 999
Study 19318900 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 999
Study 17365992 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 32
Study 17365992 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 17365992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 32
Study 15125124 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted knee arthroplasty
Number of subjects: 70
Study 11238150 — intervention group
Group type: EXPERIMENTAL
Intervention: Relenza Diskhaler
Number of subjects: 73
Study 11238150 — intervention group
Group type: COMPARATOR
Intervention: Turbohaler
Number of subjects: 73
Study 9595999 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral injection of echo contrast medium
Number of subjects: 44
Study 9595999 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral injection of echo contrast medium plus Valsalva maneuver
Number of subjects: 44
Study 9595999 — intervention group
Group type: COMPARATOR
Intervention: Ante cubital injection of echo contrast medium
Number of subjects: 44
Study 9595999 — intervention group
Group type: COMPARATOR
Intervention: Ante cubital injection of echo contrast medium plus Valsalva maneuver
Number of subjects: 44
Study 8054291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 7.5 mg
Number of subjects: 32
Study 8054291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2536410 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt and peroxide oral hygiene regimen
Number of subjects: 171
Study 2536410 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral hygiene methods
Number of subjects: 171
Study 803730 — intervention group
Group type: EXPERIMENTAL
Intervention: Bactrim for three months
Number of subjects: 96
Study 803730 — intervention group
Group type: COMPARATOR
Intervention: Placebo for three months
Number of subjects: 96
Study 30719632 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 372
Study 30719632 — intervention group
Group type: COMPARATOR
Intervention: Combined rituximab (US-RTX and EU-RTX)
Number of subjects: 372
Study 30719632 — intervention group
Group type: COMPARATOR
Intervention: US-RTX
Number of subjects: 372
Study 30719632 — intervention group
Group type: COMPARATOR
Intervention: EU-RTX
Number of subjects: 372
Study 30719632 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10 and rituximab
Number of subjects: 372
Study 27436543 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5-mm hydrophilic implants placed with osteotome sinus floor elevation (OSFE)
Number of subjects: 38
Study 27436543 — intervention group
Group type: COMPARATOR
Intervention: Standard implants placed with lateral sinus floor elevation
Number of subjects: 38
Study 27436543 — intervention group
Group type: COMPARATOR
Intervention: Long implant group
Number of subjects: 38
Study 25376753 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 109
Study 25376753 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 109
Study 23736112 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Number of subjects: 145
Study 23736112 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8mg
Number of subjects: 145
Study 23736112 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide sustained-release 1.5mg
Number of subjects: 145
Study 23736112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 21487155 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 min rest interval (1RI)
Number of subjects: 28
Study 21487155 — intervention group
Group type: COMPARATOR
Intervention: 3 min rest interval (3RI)
Number of subjects: 28
Study 19883185 — intervention group
Group type: EXPERIMENTAL
Intervention: Total tonsillectomy (TE)
Number of subjects: 67
Study 19883185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillotomy (TT)
Number of subjects: 67
Study 19883185 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 16548305 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer (3M Transbond Plus) combined with Transbond XT paste
Number of subjects: 62
Study 16548305 — intervention group
Group type: COMPARATOR
Intervention: Conventional acid-etching (Orthosolo primer and Enlight adhesive paste)
Number of subjects: 62
Study 16548305 — intervention group
Group type: EXPERIMENTAL
Intervention: Molar tube bonding with self-etching primer
Number of subjects: 62
Study 16548305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular tubes
Number of subjects: 62
Study 16548305 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided tubes
Number of subjects: 62
Study 16548305 — intervention group
Group type: EXPERIMENTAL
Intervention: Second molar tubes
Number of subjects: 62
Study 15719741 — intervention group
Group type: EXPERIMENTAL
Intervention: Weitai capsule (WTC), 4 capsules, 3 times a day for 3 months
Number of subjects: 62
Study 15719741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no WTC)
Number of subjects: 62
Study 15719741 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 62
Study 12884459 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0
Study 12884459 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin
Number of subjects: 0
Study 10510988 — intervention group
Group type: EXPERIMENTAL
Intervention: IV unfractionated heparin (UFH) - loading dose: 5000 U IV; initial infusion, 1250‐1280 U/h
Number of subjects: 961
Study 7718899 — intervention group
Group type: EXPERIMENTAL
Intervention: CY‐TBI (120 mg/kg of cyclophosphamide followed by total body irradiation)
Number of subjects: 120
Study 7718899 — intervention group
Group type: EXPERIMENTAL
Intervention: BU‐CY (16 mg/kg of busulfan followed by 120 mg/kg of cyclophosphamide)
Number of subjects: 120
Study 7718899 — intervention group
Group type: EXPERIMENTAL
Intervention: CY‐TBI
Number of subjects: 120
Study 7718899 — intervention group
Group type: EXPERIMENTAL
Intervention: BU‐CY
Number of subjects: 120
Study 7718899 — intervention group
Group type: EXPERIMENTAL
Intervention: SDTBI
Number of subjects: 120
Study 7718899 — intervention group
Group type: EXPERIMENTAL
Intervention: FTBI
Number of subjects: 120
Study 7718899 — intervention group
Group type: EXPERIMENTAL
Intervention: MoAb (anti‐interleukin‐2 receptor monoclonal antibody)
Number of subjects: 120
Study 7718899 — intervention group
Group type: COMPARATOR
Intervention: No MoAb
Number of subjects: 120
Study 2391395 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 39304 alone
Number of subjects: 9
Study 2391395 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 39304 with antacid
Number of subjects: 9
Study 2391395 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 39304 with cimetidine
Number of subjects: 9
Study 6792073 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral diet (1.5 g amino acid . kg‐1 . d‐1 and 7.6 g carbohydrate kg . d‐1)
Number of subjects: 30
Study 6792073 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased carbohydrate infusion (1.5 g amino acids . kg‐1 . d‐1 and 12 g carbohydrate . kg‐1 . d‐1)
Number of subjects: 30
Study 6792073 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-fold amino acid intake (3.0 g . kg‐1 . d‐1 and 7.6 g carbohydrates . kg‐1 . d‐1)
Number of subjects: 30
Study 31663981 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-μg estradiol (E2) softgel vaginal insert
Number of subjects: 50
Study 31663981 — intervention group
Group type: COMPARATOR
Intervention: 25-μg estradiol (E2) softgel vaginal insert
Number of subjects: 50
Study 31663981 — intervention group
Group type: COMPARATOR
Intervention: Reference product (control)
Number of subjects: 50
Study 29741558 — intervention group
Group type: EXPERIMENTAL
Intervention: High-egg diet (≥12 eggs/wk)
Number of subjects: 128
Study 29741558 — intervention group
Group type: COMPARATOR
Intervention: Low-egg diet (<2 eggs/wk)
Number of subjects: 128
Study 26170395 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 repeated doses of albendazole
Number of subjects: 2436